From QAAPAPLE 1 to QAAPAPLE 2: how do we move from one algorithm to another one with Long Acting Antipsychotics (LAIs)

References

• McIntyre JS, Charles S, Anzia D, et al. 2010. Practice guideline for the psychiatric evaluation of adults. 2nd ed. APA. Jun 2006. Washington, DC: American Psychiatric Association Publishing. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/psychevaladults.pdf
   Google Scholar
• Toprac MG, Rush AJ, Conner TM, et al. The Texas Medication Algorithm Project and patient and family education program: a consumer-guided initiative. J Clin Psychiatry. 2000;61(7):477–486.
   PubMed Web of Science ®Google Scholar
• Chiles JA, Miller AL, Crismon ML, et al. The Texas Medication Algorithm Project: development and implementation of the schizophrenia algorithm. Psychiatric Serv. 1999;50:69–74.
   PubMed Web of Science ®Google Scholar
• Mellman TA, Miller AL, Weissman EM, et al. Evidence-based pharmacologic treatment for people with severe mental illness: a focus on guidelines and algorithms. Psychiatric Serv. 2001;52(5):619–625.
   PubMed Web of Science ®Google Scholar
• Stip E, Abdel-Baki A, Bloom D, et al. Long-acting injectable antipsychotics: an expert opinion from the Association des médecins psychiatres du Québec. Can J Psychiatry. 2011;56(6):367–376.
   PubMed Web of Science ®Google Scholar
• Healy DJ, Goldman M, Florence T, et al. A survey of psychiatrists’ attitudes toward treatment guidelines. Community Ment Health J. 2004;40(2):177–184.
   PubMed Web of Science ®Google Scholar
• Zhornitsky S, Stip E. Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review. Schizophr Res Treatment. 2012;2012(12):1–12.
   PubMedGoogle Scholar
• Stip E, Abdel-Baki A, Roy M-A, et al. Long-acting antipsychotics: the QAAPAPLE algorithm review. Can J Psychiatry. 2019;64(10):697–707.
   PubMed Web of Science ®Google Scholar
• Kane JM, Schooler NR, Marcy P, et al. Patients with early-phase schizophrenia will accept treatment with sustained-release medication (Long-Acting Injectable Antipsychotics): results from the recruitment phase of the PRELAPSE trial. J Clin Psychiatry. 2019;80(3). DOI:10.4088/JCP.18m12546.
   Web of Science ®Google Scholar
• Lee K. The long-acting injectable antipsychotics in clinical practice. J Korean Neuropsychiatr Assoc. 2019;58(1):29–37.
   Google Scholar
• Arango C, Baeza I, Bernardo M, et al. Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain. Revista de Psiquiatríay Salud Mental (English Edition). 2019;12(2):92–105.
   PubMed Web of Science ®Google Scholar
• Kim HO, Seo GH, Lee BC. Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia. Ann Gen Psychiatry. 2020;19(1):1–7.
   PubMed Web of Science ®Google Scholar
• Lachaine J, Lapierre ME, Abdalla N, et al. Impact of switching to long-acting injectable antipsychotics on health services use in the treatment of schizophrenia. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2015;60(3 Suppl 2):S40.
   PubMedGoogle Scholar
• Abdel‐Baki A, Thibault D, Medrano, et al. Long‐acting antipsychotic medication as first‐line treatment of first‐episode psychosis with comorbid substance use disorder. Early Interv Psychiatry. 2020;14(1):69–79.
   PubMed Web of Science ®Google Scholar
• Stip E, Lachaine J. Real-world effectiveness of long-acting antipsychotic treatments in a nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder and other diagnoses in Quebec. Ther Adv Psychopharmacol. 2018;8(11):287–301.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603–609.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2012;40(1):192–213.
   PubMed Web of Science ®Google Scholar
• Kishi T, Oya K, Iwata N. Long-acting injectable antipsychotics for prevention of relapse in bipolar disorder: a systematic review and meta-analyses of randomized controlled trials. Int J Neuropsychopharmacol. 2016;19(9):pyw038.
   PubMed Web of Science ®Google Scholar
• Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry. 2013;74(6):568–575.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957–965.
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Kempton MJ, Rosenheck RA. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol. 2013;28(2):57–66.
   PubMed Web of Science ®Google Scholar
• Cameron C, Zummo J, Desai D, et al. Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies. Curr Med Res Opin. 2018;34(4):725–733.
   PubMed Web of Science ®Google Scholar
• Misawa F, Kishimoto T, Hagi K, et al. Safety and tolerability of long-acting injectable versus oral antipsychotics: a metaanalysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016;176(2–3):220–230.
   PubMed Web of Science ®Google Scholar
• Ostuzzi G, Bighelli I, So R, et al. Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies. Schizophr Res. 2017;183:10–21.
   PubMed Web of Science ®Google Scholar
• Pae CU, Wang SM, Han C, et al. Comparison between long acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison. Int Clin Psychopharmacol. 2017;32(5):235–248.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Hagi K, Nitta M, et al. Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies. Schizophrenia Bull. 2017;44(3):603–619.
   Web of Science ®Google Scholar
• Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72(8):822–829.
   PubMed Web of Science ®Google Scholar
• La¨hteenvuo M, Tanskanen A, Taipale H, et al. Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder. JAMA Psychiatry. 2018;75(4):347–355.
   PubMed Web of Science ®Google Scholar
• Taipale H, Mehta¨la¨ J, Tanskanen A, et al. Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia – a nationwide study with 20-year follow-up. Schizophr Bull. 2018;44(6):1381–1387.
   PubMed Web of Science ®Google Scholar
• Taipale H, Mittendorfer-Rutz E, Alexanderson K, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2017 Jul;197:274–280.
   PubMed Web of Science ®Google Scholar
• Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1–3):83–92.
   PubMed Web of Science ®Google Scholar
• Kahn DA, Docherty JP, Carpenter D. Consensus methods in practice guideline development: a review and description of a new method. Psychopharmacol Bull. 1997;33(4):631–639.
   PubMedGoogle Scholar
• Barnes TR, Drake R, Paton C, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020 Jan;34(1):3–78. DOI:10.1177/0269881119889296. Epub 2019 Dec 12. PMID:31829775.
   Google Scholar
• Ostuzzi G, Barbui C. Comparative effectiveness of long-acting antipsychotics: issues and challenges from a pragmatic randomised study. Epidemiol Psychiatr Sci. 2016;25:21–23.
   PubMed Web of Science ®Google Scholar
• Kurata T, Hashimoto T, Suzuki H. Concurrent, successful management of bipolar I disorder with comorbid alcohol dependence via aripiprazole long‐acting injection: a case report. Neuropsychopharmacol Rep. 2019;39:238–240.
   PubMedGoogle Scholar
• Keramatian K, Chakrabarty T, Yatham LN. Long-acting injectable second-generation/atypical antipsychotics for the management of bipolar disorder: a systematic review. CNS Drugs. 2019;33:431–456.
   PubMed Web of Science ®Google Scholar
• Kane JM, Agid O, Baldwin ML, et al. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry. 2019;80:12123.
   Web of Science ®Google Scholar
• Gorwood P, Bouju S, Deal C, et al. Predictive factors of functional remission in patients with early to mid-stage schizophrenia treated by long acting antipsychotics and the specific role of clinical remission. Psychiatry Res. 2019;281:112560.
   PubMed Web of Science ®Google Scholar